Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Non-nucleoside Reverse Transcriptase Inhibitor
RDEA 806 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates potent inhibitory activity against both wild-type and NNRTI-resistant HIV-1 strains, with an EC50 of 3.05 nM. This compound's selective action on reverse transcriptase makes it a valuable tool for studying HIV replication and developing antiviral therapies. Research applications include evaluating resistance patterns and assessing the efficacy of combination treatments in HIV research. -
HIV-1 Reverse Transcriptase Inhibitor
Melanochromone is an inhibitor of HIV-1 reverse transcriptase, demonstrating significant anti-HIV-1 activity. This compound is utilized in research focusing on HIV-1 infection and its mechanisms, contributing to the understanding of viral replication and potential therapeutic interventions. -
Reverse Transcriptase Inhibitor
PNU-103657 is an orally active reverse transcriptase inhibitor, demonstrating an IC50 value of 0.51 μM against wild-type enzyme. This compound exhibits significant antiviral activity, making it a valuable tool in research targeting viral infections, particularly in the context of HIV and related immune system disorders. -
HIV-1 Reverse Transcriptase Inhibitor
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity, with an IC90 of 2.0 nM against wild-type RF virus. Additionally, DPC-082 effectively inhibits a variety of single and multiple amino acid substituted HIV-1 mutant strains, making it a valuable tool for research into HIV resistance mechanisms and therapeutic development. -
Reverse Transcriptase Inhibitor
Niglizin is a noncompetitive inhibitor of reverse transcriptase, demonstrating significant efficacy in suppressing HIV replication. This compound exhibits a synergistic effect when used in conjunction with Zidovudine, enhancing its antiviral activity. Niglizin is valuable for research applications focused on HIV infection and the development of antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
HI-280 is an HIV-1 reverse transcriptase inhibitor that disrupts the replication cycle of the virus. Its primary mechanism involves targeting the reverse transcriptase enzyme, critical for the transcription of viral RNA into DNA. HI-280 holds potential for research applications focused on the mechanisms of HIV infection and the development of antiretroviral therapies. -
Non-nucleoside Reverse Transcriptase Inhibitor
VRX-480773 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high specificity for HIV-1, demonstrating an EC50 of 0.14 nM against wild-type strains. This compound exhibits no inhibitory effects on HIV-2, HBV, or HCV, and does not affect human DNA polymerase α/β. Additionally, VRX-480773 maintains efficacy against Efavirenz-resistant HIV-1 variants, with EC50 values generally below 1 nM. Its unique properties make it a valuable tool for research into HIV/AIDS. -
Non-nucleoside Reverse Transcriptase Inhibitor
HI-207 is a non-nucleoside reverse transcriptase inhibitor with demonstrated anti-HIV activity. It exhibits an IC50 value of 0.27 μM in PBMC/p24 inhibition assays, making it a potent candidate for studies investigating HIV infection mechanisms and therapeutic interventions. This compound is useful for researchers focusing on antiviral drug development and the modulation of HIV replication. -
HIV-1 Reverse Transcriptase Inhibitor
R-82150 is an HIV-1 reverse transcriptase inhibitor that functions by binding to the non-substrate binding site of the reverse transcriptase enzyme, effectively blocking the reverse transcription of viral RNA. This mechanism inhibits viral replication in HIV-1, while showing no effect on HIV-2, other RNA viruses, or DNA viruses. R-82150 is primarily utilized in research focused on understanding HIV-1 replication and therapeutic interventions. -
Nucleoside Reverse Transcriptase Inhibitor
Lamivudine-13C,15N2 is a labeled impurity of Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). This compound effectively inhibits the reverse transcriptase activity of HIV-1 and HIV-2, as well as that of the hepatitis B virus, making it valuable in antiviral research. It is utilized in studies aiming to understand the pharmacokinetics and metabolic pathways of Lamivudine and its derivatives. -
HIV-1 Reverse Transcriptase Inhibitor
Mesoxalate, a dicarboxylic and ketonic acid, serves as an inhibitor of HIV-1 reverse transcriptase (RT). It exerts biological activity with an IC50 value of 2.2 μM, making it a valuable tool for studying the inhibition of HIV replication. Mesoxalate is applicable in research focusing on antiviral therapies targeting retroviral enzymes. -
HIV-1 Reverse Transcriptase Inhibitor
L-702007 is a potent inhibitor of HIV-1 reverse transcriptase, a critical enzyme in the life cycle of the HIV virus. By obstructing viral replication, it exhibits significant antiviral activity, making it a valuable tool in HIV research. This compound is instrumental in studying the mechanisms of HIV infection and testing potential antiviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
Non-Nucleoside Reverse Transcriptase Inhibitor
DPC 961 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. It exerts its biological activity by non-competitively inhibiting the enzymatic function of reverse transcriptase, effectively blocking viral replication. This compound is primarily utilized in research focused on AIDS and the mechanisms of HIV pathogenesis. -
Non-nucleoside Reverse Transcriptase Inhibitor
DPC 963 is an oral active non-nucleoside reverse transcriptase inhibitor that demonstrates an IC50 of 18 nM. This compound is primarily utilized in the study of HIV, providing insights into reverse transcription processes and potential therapeutic strategies. Its potent inhibitory activity makes DPC 963 a valuable tool for research in antiviral drug development and HIV pathogenesis. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies. -
Anti-HIV Nucleoside Reverse Transcriptase Inhibitor
CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research. -
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
Nucleoside Reverse Transcriptase Inhibitor
Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with notable antiviral activity against HIV, HBV, and HCV. It exhibits strong inhibition of HIV-1 and HIV-2, with EC50 values ranging from 0.018 to 6.92 nM, and effectively targets NRTI-resistant strains. Additionally, Azvudine serves as a click chemistry reagent, featuring an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those with DBCO or BCN groups, making it suitable for advanced chemical biology applications. -
Reverse Transcriptase Inhibitor
FNC-TP is the intracellular active form of the nucleoside reverse transcriptase inhibitor (NRTI) FNC, targeting reverse transcriptase enzymes. This compound exhibits potent antiviral activity against HIV, HBV, and HCV. Additionally, FNC-TP serves as a versatile click chemistry reagent, featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne, DBCO, or BCN-containing molecules, facilitating advanced research applications in chemical biology. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate TEA is a potent reverse transcriptase inhibitor that functions by terminating the elongation of viral nucleic acids. It effectively inhibits the reverse transcriptase of HIV and HBV, thereby obstructing viral replication. Additionally, Lamivudine triphosphate TEA targets the RNA-dependent RNA polymerase (RdRp) of the NS5B subunit in HCV, and can be incorporated into the RNA by the RdRp of SARS-CoV-2, interrupting the synthesis and leading to a decrease in mutations in the viral genome. This makes it a critical reagent for research in antiviral therapies and viral replication studies. -
Reverse Transcriptase Inhibitor
Lamivudine salicylate is a nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against HIV reverse transcriptase 1/2 and hepatitis B virus reverse transcriptase. Its oral bioavailability and ability to penetrate the central nervous system make it a valuable compound for anti-viral research. Lamivudine salicylate is widely utilized in studies focused on the treatment and management of HIV and hepatitis B infections. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development. -
Nucleoside Reverse Transcriptase Inhibitor
Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
NNRT inhibitor
MK-1439 is a non-nucleoside reverse transcriptase inhibitor -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
NNRT inhibitor
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. -
NNRT inhibitor
Delavirdine is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). -
Transcriptase inhibitor
Abacavir sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS. -
NNRT inhibitor
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. -
NNRT inhibitor
Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. -
NRT inhibitor
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI). -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
nucleotide reverse transcriptase inhibitor
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
NNRT inhibitor
Elsulfavirine is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. -
non-nucleoside reverse transcriptase inhibitor
Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). -
nucleoside reverse transcriptase inhibitor
Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection. -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
nucleoside reverse transcriptase (RT) inhibitor
4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC50 of 98 nM in MT-4 cells for anti-HIV-1 activity. -
XMRV inhibitor
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (XMRV) inhibitor with a CC50 of 43.5 μM in MCF-7 cells. -
NRTI Inhibitor
Zidovudine is a nucleoside analog reverse-transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the treatment of HIV/AIDS infection. Azidothymidine decreases CRISPR-mediated homology directed repair (HDR) efficiency.
